Stockscreener 앱 받기
1.02
3.66%
0.036
시간 외 거래:
1.05
0.03
+2.94%
전일 마감가:
$0.984
열려 있는:
$0.9889
하루 거래량:
3.95M
Relative Volume:
1.02
시가총액:
$273.62M
수익:
$232.40M
순이익/손실:
$-20.51M
주가수익비율:
-13.23
EPS:
-0.0771
순현금흐름:
$60.04M
1주 성능:
+16.85%
1개월 성능:
-3.77%
6개월 성능:
-36.65%
1년 성능:
-70.86%
1일 변동 폭
$0.9801
$1.05
1주일 범위
$0.8396
$1.05
52주 변동 폭
$0.8227
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.02 | 251.81M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics sees Vafseo uptake rising as access and pipeline milestones near - MSN
Akebia Strengthens Patent Portfolio with New Grant for Vafseo (A - GuruFocus
Akebia receives new patent, extension eligibility for Vafseo - Investing.com
Akebia receives new patent, extension eligibility for Vafseo By Investing.com - Investing.com South Africa
Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease - marketscreener.com
Akebia Therapeutics Announces New Patent and Patent Extension Eligibility for Vafseo® (vadadustat) Strengthening Intellectual Property Portfolio - Quiver Quantitative
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewswire
Akebia’s Vafseo gains traction as $106B pharma M&A reshapes sector - MSN
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near - MarketBeat
AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026 - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Stock Price, Quote & Chart | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
AKBA Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsEarnings Cycle Report - thelegaladvocate.com
AKBA Q1 2026 Earnings: EPS Misses Estimates as Stock Holds SteadyEarnings Surprise Stocks - thelegaladvocate.com
Akebia Therapeutics (AKBA) Edges Higher at $1.04 – Key Levels in FocusFair Value Gap - thelegaladvocate.com
Promising Penny Stocks To Consider In May 2026 - Yahoo Finance
Akebia Therapeutics Inc. (AKBA) Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock UnchangedQuarterly Profit Report - thelegaladvocate.com
AKBA Technical Analysis & Stock Price Forecast - Intellectia AI
Akebia Therapeutics (AKBA) Holds Steady at $1.02 as Stock Consolidates Near Key SupportMomentum Stock Picks - newsline.com
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Akebia plunges 20% on muted Q1 print - MSN
Number of shareholders of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan
HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat
TradingKey - TradingKey
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance
Akebia Q1 2026 earnings preview - MSN
HC Wainwright Expects Lower Earnings for Akebia Therapeutics - MarketBeat
Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - Sahm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright - The Globe and Mail
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Akebia Therapeutics Inc 주식 (AKBA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Malabre Richard C | SVP, Chief Accounting Officer |
Feb 02 '26 |
Sale |
1.39 |
49,524 |
68,838 |
299,390 |
| Grund Nicholas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.39 |
84,829 |
117,912 |
561,750 |
| Burke Steven Keith | SVP, Chief Medical Officer |
Feb 02 '26 |
Sale |
1.39 |
67,658 |
94,045 |
948,432 |
| Rucci Carolyn M. | SVP, Chief Legal Officer |
Feb 02 '26 |
Sale |
1.39 |
69,772 |
96,983 |
588,378 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Feb 02 '26 |
Sale |
1.39 |
34,951 |
48,582 |
672,635 |
| Butler John P. | CEO and President |
Feb 02 '26 |
Sale |
1.39 |
341,305 |
474,414 |
3,206,233 |
0.95%
1.13%
자본화:
|
볼륨(24시간):